DNA methylation biomarkers: Cancer and beyond

Genes

Volumn 5, Issue 3, 2014, Pages 821-864

  Mikeska, Thomas ^a   Craig, Jeffrey M ^b,c  

^a Genetic Technologies Limited   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Autism; Bipolar disorder; Cancer; Depression; Diabetes; Environmental factors; Obesity; Schizophrenia; Smoking; Stress

Indexed keywords

BIOLOGICAL MARKER; BISULFITE; DNA METHYLATION BIOMARKER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GENOMIC DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR PITX2; UNCLASSIFIED DRUG;

ADULT; AGING; AHRR GENE; AREA UNDER THE CURVE; BIRTH; BISULFITE PYROSEQUENCING; CANCER PROGNOSIS; CELLULAR DISTRIBUTION; CELLULAR HOMOGENEITY; CHILDHOOD; CHRONIC DISEASE; CPG ISLAND; CPT1A GENE; DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE PHENOMENON; DISEASE LATENCY; DISEASE RISK MODEL; DNA METHYLATION; DNA METHYLATION ASSAY; DNA SEQUENCE; ENOS GENE; ENVIRONMENTAL FACTOR; EPIGENETICS; FALSE POSITIVE RESULT; GENE; GENERAL ASPECTS OF DISEASE; GENETIC DISORDER; GENOMIC IMPRINTING DISORDER; HP1BP3 GENE; HUMAN; INVESTIGATIVE PROCEDURES; LEP GENE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METHYLATION SENSITIVE HIGH RESOLUTION MELTING; METHYLATION SENSITIVE MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; MGMT GENE; NEOPLASM; NONBIOLOGICAL MODEL; NONHUMAN; NR3C1 GENE; PHENOTYPE; PITX2 GENE; POLYMERASE CHAIN REACTION; PPARG GENE; PREDICTIVE VALUE; PYROSEQUENCING; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RXRA GENE; SENSITIVITY AND SPECIFICITY; SHOX2 GENE; SMOKING; SNRPN GENE; STRESS; UBE3A GENE;

EID: 84923642506     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes5030821     Document Type: Review

References (293)

1. Naylor, S. Biomarkers: Current perspectives and future prospects. Expert Rev. Mol. Diagn. 2003, 3, 525–529.
2. Mayeux, R. Biomarkers: Potential uses and limitations. NeuroRx2004, 1, 182–188.
3. Strimbu, K.; Tavel, J.A. What are biomarkers? Curr. Opin. HIV AIDS2010, 5, 463–466.
4. Ogino, S.; Lochhead, P.; Chan, A.T.; Nishihara, R.; Cho, E.; Wolpin, B.M.; Meyerhardt, J.A.; Meissner A.; Schernhammer, E.S.; Fuchs C.S.; et al.Molecular pathological epidemiology of epigenetics: Emerging integrative science to analyze environment, host, and disease. Mod.Pathol. 2013, 26, 465–484.
5. Bird A. Perceptions of epigenetics. Nature2007, 447, 396–398.
6. Teh, A.L.; Pan H.; Chen L.; Ong, M.L.; Dogra, S.; Wong, J.; Macisaac, J.L.; Mah, S.M.; McEwen, L.M.; Saw S.M.; et al.The effect of genotype and in utero environment on inter-individual variation in neonate DNA methylomes. Genome Res. 2014, doi:10.1101/gr.171439.113.
7. De Laat, W.; Duboule, D. Topology of mammalian developmental enhancers and their regulatory landscapes. Nature2013, 502, 499–506.
8. Quina, A.S.; Buschbeck, M.; di Croce, L. Chromatin structure and epigenetics. Biochem. Pharmacol. 2006, 72, 1563–1569.
9. Jurkowska R.Z.; Jurkowski, T.P.; Jeltsch, A. Structure and function of mammalian DNA methyltransferases. Chembiochem2011, 12, 206–222.
10. Jeltsch, A.; Jurkowska R.Z. New concepts in DNA methylation. Trends Biochem. Sci. 2014, 39, 310–318.
11. Deaton, A.M.; Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011, 25, 1010–1022.
12. Gardiner-Garden, M.; Frommer M. CpG islands in vertebrate genomes. J. Mol. Biol. 1987, 196, 261–282.
13. Takai, D.; Jones, P.A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. USA2002, 99, 3740–3745.
14. Zhao, Z.; Han, L. CpG islands: Algorithms and applications in methylation studies. Biochem. Biophys. Res. Commun. 2009, 382, 643–645.
15. Wu, H.; Caffo, B.; Jaffee, H.A.; Irizarry, R.A.; Feinberg, A.P. Redefining CpG islands using hidden Markov models. Biostatistics2010, 11, 499–514.
16. Chuang, L.Y.; Huang H.C.; Lin, M.C.; Yang, C.H. Particle swarm optimization with reinforcement learning for the prediction of CpG islands in the human genome. PLoS One2011, 6, e21036.
17. Kulis, M.; Queiros, A.C.; Beekman, R.; Martin-Subero, J.I. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochim. Biophys. Acta2013, 1829, 1161–1174.
18. Oberdoerffer, S. A conserved role for intragenic DNA methylation in alternative pre-mRNA splicing. Transcription2012, 3, 106–109.
19. Illingworth R.S.; Gruenewald-Schneider, U.; Webb S.; Kerr A.R.; James K.D.; Turner, D.J.; Smith C.; Harrison D.J.; Andrews R.; Bird A.P. Orphan CpG islands identify numerous conserved promoters in the mammalian genome. PLoS Genet. 2010,6, e1001134.
20. Irizarry, R.A.; Ladd-Acosta, C.; Wen, B.; Wu, Z.; Montano, C.; Onyango, P.; Cui, H.; Gabo, K.; Rongione, M.; Webster M.; et al.The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet.2009, 41, 178–186.
21. Ehrlich, M. DNA methylation and cancer-associated genetic instability. Adv. Exp. Med. Biol. 2005, 570, 363–392.
22. Choi, J.D.; Lee, J.S. Interplay between Epigenetics and Genetics in Cancer. Genomics Inform. 2013, 11, 164–173.
23. Heng, H.H.; Liu, G.; Stevens, J.B.; Bremer, S.W.; Ye, K.J.; Ye, C.J. Genetic and epigenetic heterogeneity in cancer: The ultimate challenge for drug therapy. Curr. Drug Targets2010, 11, 1304–1316.
24. Huang S. Genetic and non-genetic instability in tumor progression: Link between the fitness landscape and the epigenetic landscape of cancer cells. Cancer Metastasis Rev. 2013, 32, 423–448.
25. Stecklein, S.R.; Jensen, R.A.; Pal, A. Genetic and epigenetic signatures of breast cancer subtypes. Front. Biosci. 2012, 4, 934–949.
26. Gluckman P.D.; Hanson, M.A.; Buklijas, T. A conceptual framework for the developmental origins of health and disease. J. Dev. Orig. Health Dis. 2010, 1, 6–18.
27. Gluckman P.D.; Hanson, M.A.; Pinal, C. The developmental origins of adult disease. Matern. Child Nutr. 2005, 1, 130–141.
28. Barker, D.J. The fetal and infant origins of adult disease. BMJ1990, 301, 1111.
29. Godfrey, K.M.; Lillycrop, K.A.; Burdge, G.C.; Gluckman P.D.; Hanson, M.A. Epigenetic mechanisms and the mismatch concept of the developmental origins of health and disease. Pediatr. Res. 2007, 61, R5–R10.
30. McNeal, C.J.; Wilson, D.P.; Christou, D.; Bush, R.L.; Shepherd, L.G.; Santiago, J.; Wu, G.Y. The use of surrogate vascular markers in youth at risk for premature cardiovascular disease. J. Pediatr. Endocrinol. Metab. 2009, 22, 195–211.
31. Urbina, E.M.; Williams, R.V.; Alpert, B.S.; Collins, R.T.; Daniels, S.R.; Hayman, L.; Jacobson, M.; Mahoney, L.; Mietus-Snyder, M.; Rocchini A.; et al.Noninvasive assessment of subclinical atherosclerosis in children and adolescents: Recommendations for standard assessment for clinical research: A scientific statement from the American Heart Association. Hypertension2009, 54, 919–950.
32. Wong, N.C.; Morley, R.; Saffery R.; Craig J.M. Archived guthrie blood spots as a novel source for quantitative DNA methylation analysis. Biotechniques2008, 45, 423–428.
33. Thirlwell, C.; Eymard, M.; Feber, A.; Teschendorff, A.; Pearce, K.; Lechner, M.; Widschwendter, M.; Beck, S. Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium HumanMethylation27 BeadChip. Methods2010, 52, 248–254.
34. Wong, N.C.; Ashley, D.; Chatterton, Z.; Parkinson-Bates, M.; Ng, H.K.; Halemba, M.S.; Kowalczyk, A.; Bedo, J.; Wang, Q.; Bell K.; et al.A distinct DNA methylation signature defines pediatric pre-B cell acute lymphoblastic leukemia. Epigenetics2012, 7, 535–541.
35. Ribel-Madsen, R.; Fraga, M.F.; Jacobsen, S.; Bork-Jensen, J.; Lara, E.; Calvanese, V.; Fernandez, A.F.; Friedrichsen, M.; Vind, B.F.; Hojlund K.; et al.Genome-wide analysis of DNA methylation differences in muscle and fat from monozygotic twins discordant for type 2 diabetes. PLoS One2012, 7, e51302.
36. Talens, R.P.; Boomsma, D.I.; Tobi, E.W.; Kremer, D.; Jukema, J.W.; Willemsen, G.; Putter, H.; Slagboom, P.E.; Heijmans, B.T. Variation, patterns, and temporal stability of DNA methylation: Considerations for epigenetic epidemiology. FASEBJ. 2010, 24, 3135–3144.
37. Souren, N.Y.; Tierling, S.; Fryns, J.P.; Derom, C.; Walter, J.; Zeegers, M.P. DNA methylation variability at growth-related imprints does not contribute to overweight in monozygotic twins discordant for BMI. Obesity2011, 19, 1519–1522.
38. Belinsky, S.A.; Palmisano, W.A.; Gilliland, F.D.; Crooks, L.A.; Divine, K.K.; Winters, S.A.; Grimes, M.J.; Harms, H.J.; Tellez, C.S.; Smith T.M.; et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 2002, 62, 2370–2377.
39. Barnes, S.K.; Ozanne, S.E. Pathways linking the early environment to long-term health and lifespan. Prog. Biophys. Mol. Biol. 2011, 106, 323–336.
40. Ollikainen, M.; Smith K.R.; Joo, E.J.; Ng, H.K.; Andronikos, R.; Novakovic, B.; Abdul Aziz, N.K.; Carlin, J.B.; Morley, R.; Saffery R.; et al.DNA methylation analysis of multiple tissues from newborn twins reveals both genetic and intrauterine components to variation in the human neonatal epigenome. Hum. Mol. Genet. 2010, 19, 4176–4188.
41. Dittrich, B.; Buiting, K.; Gross, S.; Horsthemke, B. Characterization of a methylation imprint in the Prader-Willi syndrome chromosome region. Hum. Mol. Genet. 1993, 2, 1995–1999.
42. Godfrey, K.M.; Sheppard, A.; Gluckman P.D.; Lillycrop, K.A.; Burdge, G.C.; McLean, C.; Rodford, J.; Slater-Jefferies, J.L.; Garratt, E.; Crozier S.R.; et al.Epigenetic gene promoter methylation at birth is associated with child’s later adiposity. Diabetes2011, 60, 1528–1534.
43. Lowe, R.; Rakyan V.K. Correcting for cell-type composition bias in epigenome-wide association studies. Genome Med. 2014, 6, 23.
44. Adalsteinsson, B.T.; Gudnason, H.; Aspelund, T.; Harris, T.B.; Launer, L.J.; Eiriksdottir, G.; Smith A.V.; Gudnason, V. Heterogeneity in white blood cells has potential to confound DNA methylation measurements. PLoS One2012, 7, e46705.
45. Loh, M.; Liem, N.; Lim, P.L.; Vaithilingam, A.; Cheng, C.L.; Salto-Tellez, M.; Yong, W.P.; Soong, R. Impact of sample heterogeneity on methylation analysis. Diagn. Mol. Pathol. 2010, 19, 243–247.
46. Montano, C.M.; Irizarry, R.A.; Kaufmann, W.E.; Talbot, K.; Gur, R.E.; Feinberg, A.P.; Taub, M.A. Measuring cell-type specific differential methylation in human brain tissue. Genome Biol. 2013, 14, R94.
47. Moverare-Skrtic, S.; Mellstrom, D.; Vandenput, L.; Ehrich, M.; Ohlsson, C. Peripheral blood leukocyte distribution and body mass index are associated with the methylation pattern of the androgen receptor promoter. Endocrine2009, 35, 204–210.
48. Zou, J.; Lippert, C.; Heckerman, D.; Aryee, M.; Listgarten, J. Epigenome-wide association studies without the need for cell-type composition. Nat. Methods2014, 11, 309–311.
49. Accomando, W.P.; Wiencke, J.K.; Houseman, E.A.; Nelson, H.H.; Kelsey, K.T. Quantitative reconstruction of leukocyte subsets using DNA methylation. Genome Biol. 2014, 15, R50.
50. Houseman, E.A.; Accomando, W.P.; Koestler, D.C.; Christensen, B.C.; Marsit, C.J.; Nelson, H.H.; Wiencke, J.K.; Kelsey, K.T. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinform. 2012, 13, 86.
51. Herceg, Z.; Hainaut, P. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol. Oncol. 2007, 1, 26–41.
52. Iliopoulos, D.; Guler, G.; Han, S.Y.; Johnston, D.; Druck, T.; McCorkell, K.A.; Palazzo, J.; McCue, P.A.; Baffa, R.; Huebner, K. Fragile genes as biomarkers: Epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene2005, 24, 1625–1633.
53. Verma, M.; Manne, U. Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. Crit. Rev. Oncol./Hematol. 2006, 60, 9–18.
54. Zilberman, D.; Henikoff, S. Genome-wide analysis of DNA methylation patterns. Development2007, 134, 3959–3965.
55. Zuo, T.; Tycko, B.; Liu, T.M.; Lin, J.J.; Huang T.H. Methods in DNA methylation profiling. Epigenomics2009, 1, 331–345.
56. Kalari, S.; Pfeifer, G.P. Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv. Genet. 2010, 70, 277–308.
57. Kim, M.; Long, T.I.; Arakawa, K.; Wang, R.; Yu, M.C.; Laird, P.W. DNA methylation as a biomarker for cardiovascular disease risk. PLoS One2010, 5, e9692.
58. How Kit, A.; Nielsen, H.M.; Tost, J. DNA methylation based biomarkers: Practical considerations and applications. Biochimie2012, 94, 2314–2337.
59. Michels, K.B.; Binder, A.M.; Dedeurwaerder, S.; Epstein, C.B.; Greally, J.M.; Gut, I.; Houseman, E.A.; Izzi, B.; Kelsey, K.T.; Meissner A.; et al.Recommendations for the design and analysis of epigenome-wide association studies. Nat. Methods2013, 10, 949–955.
60. Rakyan V.K.; Down T.A.; Balding, D.J.; Beck, S. Epigenome-wide association studies for common human diseases. Nat. Rev. Genet. 2011, 12, 529–541.
61. Wians, F.H. Clinical laboratory tests: Which, why, and what do the results mean? Lab Med. 2009, 40, 105–113.
62. Linnet, K.; Bossuyt, P.M.; Moons, K.G.; Reitsma, J.B. Quantifying the accuracy of a diagnostic test or marker. Clin. Chem. 2012, 58, 1292–1301.
63. Wentzensen, N.; Wacholder S. From differences in means between cases and controls to risk stratification: A business plan for biomarker development. Cancer Discov. 2013, 3, 148–157.
64. Fraga, M.F.; Esteller M. DNA methylation: A profile of methods and applications. Biotechniques 2002, 33, 632, 634, 636–649.
65. Dahl, C.; Guldberg, P. DNA methylation analysis techniques. Biogerontology2003, 4, 233–250.
66. Kristensen, L.S.; Hansen, L.L. PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin. Chem. 2009, 55, 1471–1483.
67. Hernandez, H.G.; Tse, M.Y.; Pang, S.C.; Arboleda, H.; Forero, D.A. Optimizing methodologies for PCR-based DNA methylation analysis. Biotechniques2013, 55, 181–197.
68. Jorda, M.; Peinado, M.A. Methods for DNA methylation analysis and applications in colon cancer. Mutat. Res. 2010, 693, 84–93.
69. Shen, L.; Waterland R.A. Methods of DNA methylation analysis. Curr. Opin. Clin. Nutr. Metab. Care2007, 10, 576–581.
70. Frommer M.; McDonald, L.E.; Millar, D.S.; Collis, C.M.; Watt, F.; Grigg, G.W.; Molloy, P.L.; Paul, C.L. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA1992, 89, 1827–1831.
71. Grunau, C.; Clark S.J.; Rosenthal, A. Bisulfite genomic sequencing: Systematic investigation of critical experimental parameters. Nucleic Acids Res. 2001, 29, e65.
72. Holmes, E.E.; Jung, M.; Meller, S.; Leisse, A.; Sailer, V.; Zech, J.; Mengdehl, M.; Garbe, L.A.; Uhl, B.; Kristiansen, G.; et al.Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urine. PLoS One2014, 9, e93933.
73. Tanaka, K.; Okamoto, A. Degradation of DNA by bisulfite treatment. Bioorg. Med. Chem. Lett.2007, 17, 1912–1915.
74. Munson, K.; Clark J.; Lamparska-Kupsik, K.; Smith S.S. Recovery of bisulfite-converted genomic sequences in the methylation-sensitive QPCR. Nucleic Acids Res. 2007, 35, 2893–2903.
75. Brandes J.C.; Carraway, H.; Herman, J.G. Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter. Oncogene2007, 26, 6229–6237.
76. Warnecke, P.M.; Stirzaker, C.; Melki, J.R.; Millar, D.S.; Paul, C.L.; Clark S.J. Detection and measurement of PCR bias in quantitative methylation analysis of bisulphite-treated DNA. Nucleic Acids Res. 1997, 25, 4422–4426.
77. Chhibber, A.; Schroeder, B.G. Single-molecule polymerase chain reaction reduces bias: Application to DNA methylation analysis by bisulfite sequencing. Anal. Biochem. 2008, 377, 46–54.
78. Moskalev, E.A.; Zavgorodnij, M.G.; Majorova, S.P.; Vorobjev, I.A.; Jandaghi, P.; Bure, I.V.; Hoheisel, J.D. Correction of PCR-bias in quantitative DNA methylation studies by means of cubic polynomial regression. Nucleic Acids Res. 2011, 39, e77.
79. Shen, L.; Guo, Y.; Chen X.; Ahmed, S.; Issa, J.P. Optimizing annealing temperature overcomes bias in bisulfite pcr methylation analysis. Biotechniques2007, 42, 48–58.
80. Wojdacz, T.K.; Hansen, L.L.; Dobrovic, A. A new approach to primer design for the control of PCR bias in methylation studies. BMC Res. Notes2008, 1, 54.
81. Claus, R.; Wilop, S.; Hielscher, T.; Sonnet, M.; Dahl, E.; Galm, O.; Jost, E.; Plass, C. A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. Epigenetics2012, 7, 772–780.
82. Raval, A.; Tanner, S.M.; Byrd, J.C.; Angerman, E.B.; Perko, J.D.; Chen S.S.; Hackanson, B.; Grever, M.R.; Lucas, D.M.; Matkovic J.J.; et al.Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell2007, 129, 879–890.
83. Shah, N.; Lin, B.; Sibenaller, Z.; Ryken, T.; Lee, H.; Yoon, J.G.; Rostad, S.; Foltz, G. Comprehensive analysis of MGMT promoter methylation: Correlation with MGMT expression and clinical response in GBM. PLoS One2011, 6, e16146.
84. Mikeska, T.; Candiloro, I.L.; Dobrovic, A. The implications of heterogeneous DNA methylation for the accurate quantification of methylation. Epigenomics2010, 2, 561–573.
85. Reddy, A.N.; Jiang, W.W.; Kim, M.; Benoit, N.; Taylor, R.; Clinger, J.; Sidransky, D.; Califano, J.A. Death-associated protein kinase promoter hypermethylation in normal human lymphocytes. Cancer Res. 2003, 63, 7694–7698.
86. Srinivasan, M.; Sedmak, D.; Jewell, S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am. J. Pathol. 2002, 161, 1961–1971.
87. Colella, S.; Shen, L.; Baggerly, K.A.; Issa, J.P.; Krahe, R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques2003, 35, 146–150.
88. Tost, J.; Dunker, J.; Gut, I.G. Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques2003, 35, 152–156.
89. Mikeska, T.; Felsberg, J.; Hewitt, C.A.; Dobrovic, A. Analysing DNA methylation using bisulphite pyrosequencing. Methods Mol. Biol. 2011, 791, 33–53.
90. Dejeux, E.; Audard, V.; Cavard, C.; Gut, I.G.; Terris, B.; Tost, J. Rapid identification of promoter hypermethylation in hepatocellular carcinoma by pyrosequencing of etiologically homogeneous sample pools. J. Mol. Diagn. 2007, 9, 510–520.
91. Lillycrop, K.A.; Phillips, E.S.; Torrens, C.; Hanson, M.A.; Jackson, A.A.; Burdge, G.C. Feeding pregnant rats a protein-restricted diet persistently alters the methylation of specific cytosines in the hepatic PPAR alpha promoter of the offspring. Br.J. Nutr. 2008, 100, 278–282.
92. Ehrich, M.; Nelson, M.R.; Stanssens, P.; Zabeau, M.; Liloglou, T.; Xinarianos, G.; Cantor, C.R.; Field, J.K.; van den Boom, D. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc. Natl. Acad. Sci. USA2005, 102, 15785–15790.
93. Coolen, M.W.; Statham, A.L.; Gardiner-Garden, M.; Clark S.J. Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: Critical evaluation and improvements. Nucleic Acids Res. 2007, 35, e119.
94. Wojdacz, T.K.; Dobrovic, A. Methylation-sensitive high resolution melting (MS-HRM): A new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007, 35, e41.
95. Mikeska, T.; Dobrovic, A. Methylation-sensitive high resolution melting for the rapid analysis of DNA methylation. In Epigenetics: A Reference Manual; Craig J.M., Wong, N.C., Eds.; Caister Academic Press: Norwich, UK, 2011; pp. 325–335.
96. Candiloro, I.L.; Mikeska, T.; Dobrovic, A. Closed-tube PCR methods for locus-specific DNA methylation analysis. Methods Mol. Biol. 2011, 791, 55–71.
97. Candiloro, I.L.; Mikeska, T.; Dobrovic, A. Assessing combined methylation-sensitive high resolution melting and pyrosequencing for the analysis of heterogeneous DNA methylation. Epigenetics2011, 6, 500–507.
98. Herman, J.G.; Graff, J.R.; Myohanen, S.; Nelkin, B.D.; Baylin, S.B. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA1996, 93, 9821–9826.
99. Preusser, M.; Elezi, L.; Hainfellner, J.A. Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Clin. Neuropathol. 2008, 27, 388–390.
100. Hamilton, M.G.; Roldan, G.; Magliocco, A.; McIntyre, J.B.; Parney, I.; Easaw, J.C. Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. J. Neurooncol. 2011, 102, 255–260.
101. Eads, C.A.; Danenberg, K.D.; Kawakami, K.; Saltz, L.B.; Blake, C.; Shibata, D.; Danenberg, P.V.; Laird, P.W. MethyLight: A high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000, 28, e32.
102. Rand, K.; Qu, W.; Ho, T.; Clark S.J.; Molloy, P. Conversion-specific detection of DNA methylation using real-time polymerase chain reaction (ConLight-MSP) to avoid false positives. Methods2002, 27, 114–120.
103. Bonanno, C.; Shehi, E.; Adlerstein, D.; Makrigiorgos, G.M. MS-FLAG, a novel real-time signal generation method for methylation-specific PCR. Clin. Chem. 2007, 53, 2119–2127.
104. Kristensen, L.S.; Mikeska, T.; Krypuy, M.; Dobrovic, A. Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): High-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res. 2008, 36, e42.
105. Cottrell, S.E.; Distler, J.; Goodman, N.S.; Mooney, S.H.; Kluth, A.; Olek, A.; Schwope, I.; Tetzner, R.; Ziebarth, H.; Berlin, K. A real-time PCR assay for DNA-methylation using methylation-specific blockers. Nucleic Acids Res. 2004, 32, e10.
106. Nygren, A.O.; Ameziane, N.; Duarte, H.M.; Vijzelaar, R.N.; Waisfisz, Q.; Hess, C.J.; Schouten, J.P.; Errami, A. Methylation-specific MLPA (MS-MLPA): Simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005, 33, e128.
107. Serizawa, R.R.; Ralfkiaer, U.; Dahl, C.; Lam, G.W.; Hansen, A.B.; Steven, K.; Horn, T.; Guldberg, P. Custom-designed MLPA using multiple short synthetic probes: Application to methylation analysis of five promoter CpG islands in tumor and urine specimens from patients with bladder cancer. J. Mol. Diagn. 2010, 12, 402–408.
108. Gatta, V.; Gennaro, E.; Franchi, S.; Cecconi, M.; Antonucci, I.; Tommasi, M.; Palka, G.; Coviello, D.; Stuppia, L.; Grasso, M. MS-MLPA analysis for FMR1 gene: Evaluation in a routine diagnostic setting. BMC Med. Genet. 2013, 14, 79.
109. Jeuken J.W.; Cornelissen, S.J.; Vriezen, M.; Dekkers, M.M.; Errami, A.; Sijben, A.; Boots-Sprenger, S.H.; Wesseling, P. MS-MLPA: An attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab. Investig. 2007, 87, 1055–1065.
110. Homig-Holzel, C.; Savola, S. Multiplex ligation-dependent probe amplification (MLPA) in tumor diagnostics and prognostics. Diagn. Mol. Pathol. 2012, 21, 189–206.
111. Tano, K.; Shiota, S.; Collier, J.; Foote, R.S.; Mitra, S. Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine. Proc. Natl. Acad. Sci. USA1990, 87, 686–690.
112. Natarajan, A.T.; Vermeulen, S.; Darroudi, F.; Valentine, M.B.; Brent, T.P.; Mitra, S.; Tano, K. Chromosomal localization of human O6-methylguanine-DNA methyltransferase (MGMT) gene by in situ hybridization. Mutagenesis1992, 7, 83–85.
113. Nutt, C.L.; Costello, J.F.; Bambrick, L.L.; Yarosh, D.B.; Swinnen, L.J.; Chambers, A.F.; Cairncross, J.G. O6-methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage. Can. J. Neurol. Sci. 1995, 22, 111–115.
114. Mineura, K.; Yanagisawa, T.; Watanabe, K.; Kowada, M.; Yasui, N. Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy. Int.J. Cancer1996, 69, 420–425.
115. Silber, J.R.; Bobola, M.S.; Ghatan, S.; Blank, A.; Kolstoe, D.D.; Berger, M.S. O6-methylguanine-DNA methyltransferase activity in adult gliomas: Relation to patient and tumor characteristics. Cancer Res. 1998, 58, 1068–1073.
116. Esteller M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S.N.; Hidalgo, O.F.; Vanaclocha, V.; Baylin, S.B.; Herman, J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343, 1350–1354.
117. Hegi M.E.; Diserens, A.C.; Godard, S.; Dietrich P.Y.; Regli, L.; Ostermann, S.; Otten, P.; van Melle, G.; de Tribolet, N.; Stupp, R. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 2004, 10, 1871–1874.
118. Paz, M.F.; Yaya-Tur, R.; Rojas-Marcos, I.; Reynes, G.; Pollan, M.; Aguirre-Cruz, L.; Garcia-Lopez, J.L.; Piquer, J.; Safont, M.J.; Balana C.; et al.CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin. Cancer Res. 2004, 10, 4933–4938.
119. Blanc, J.L.; Wager, M.; Guilhot, J.; Kusy, S.; Bataille, B.; Chantereau, T.; Lapierre, F.; Larsen, C.J.; Karayan-Tapon, L. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J. Neurooncol. 2004, 68, 275–283.
120. Hegi M.E.; Diserens, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.; Mason, W.; Mariani L.; et al.MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352, 997–1003.
121. Wick, W.; Weller, M.; van den Bent, M.; Sanson, M.; Weiler, M.; von Deimling, A.; Plass, C.; Hegi M.; Platten, M.; Reifenberger, G. MGMT testing-the challenges for biomarker-based glioma treatment. Nat. Rev. Neurol. 2014, 10, 372–385.
122. Christians, A.; Hartmann, C.; Benner, A.; Meyer, J.; von Deimling, A.; Weller, M.; Wick, W.; Weiler, M. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One2012, 7, e33449.
123. Karayan-Tapon, L.; Quillien, V.; Guilhot, J.; Wager, M.; Fromont, G.; Saikali S.; Etcheverry, A.; Hamlat, A.; Loussouarn, D.; Campion L.; et al.Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J. Neurooncol. 2010, 97, 311–322.
124. Mikeska, T.; Bock, C.; el-Maarri, O.; Hubner, A.; Ehrentraut, D.; Schramm, J.; Felsberg, J.; Kahl, P.; Buttner, R.; Pietsch T.; et al.Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J. Mol. Diagn. 2007, 9, 368–381.
125. Quillien, V.; Lavenu, A.; Karayan-Tapon, L.; Carpentier, C.; Labussiere, M.; Lesimple, T.; Chinot, O.; Wager, M.; Honnorat, J.; Saikali S.; et al.Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer2012, 118, 4201–4211.
126. Weller, M.; Stupp, R.; Reifenberger, G.; Brandes A.A.; van den Bent, M.J.; Wick, W.; Hegi M.E. MGMT promoter methylation in malignant gliomas: Ready for personalized medicine? Nat. Rev. Neurol. 2010, 6, 39–51.
127. Mikeska, T.; Bock, C.; Do, H.; Dobrovic, A. DNA methylation biomarkers in cancer: Progress towards clinical implementation. Expert Rev. Mol. Diagn. 2012, 12, 473–487.
128. Li, Y.W.; Kong, F.M.; Zhou, J.P.; Dong, M. Aberrant promoter methylation of the vimentin gene may contribute to colorectal carcinogenesis: A meta-analysis. Tumour Biol. 2014, 35, 6783–6790.
129. Payne S.R. From discovery to the clinic: The novel DNA methylation biomarker (m)sept9 for the detection of colorectal cancer in blood. Epigenomics2010, 2, 575–585.
130. Darwiche, K.; Zarogoulidis, P.; Baehner, K.; Welter, S.; Tetzner, R.; Wohlschlaeger, J.; Theegarten, D.; Nakajima, T.; Freitag, L. Assessment of shox2 methylation in ebus-tbna specimen improves accuracy in lung cancer staging. Ann. Oncol. 2013, 24, 2866–2870.
131. Dietrich D.; Hasinger, O.; Liebenberg, V.; Field, J.K.; Kristiansen, G.; Soltermann, A. DNA methylation of the homeobox genes pitx2 and shox2 predicts outcome in non-small-cell lung cancer patients. Diagn. Mol. Pathol. 2012, 21, 93–104.
132. Dietrich D.; Jung, M.; Puetzer, S.; Leisse, A.; Holmes, E.E.; Meller, S.; Uhl, B.; Schatz, P.; Ivascu, C.; Kristiansen, G. Diagnostic and prognostic value of shox2 and sept9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions. PloS One2013, 8, e84225.
133. Ilse, P.; Biesterfeld, S.; Pomjanski, N.; Fink, C.; Schramm, M. Shox2 DNA methylation is a tumour marker in pleural effusions. Cancer genomics proteomics2013, 10, 217–223.
134. Kneip, C.; Schmidt, B.; Seegebarth, A.; Weickmann, S.; Fleischhacker, M.; Liebenberg, V.; Field, J.K.; Dietrich D. Shox2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J. Thorac. Oncol. 2011, 6, 1632–1638.
135. Schmidt, B.; Liebenberg, V.; Dietrich D.; Schlegel, T.; Kneip, C.; Seegebarth, A.; Flemming, N.; Seemann, S.; Distler, J.; Lewin J.; et al.Shox2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer2010, 10, 600.
136. Wu, T.; Giovannucci, E.; Welge, J.; Mallick, P.; Tang, W.Y.; Ho, S.M. Measurement of gstp1 promoter methylation in body fluids may complement psa screening: A meta-analysis. Br. J. Cancer2011, 105, 65–73.
137. Chen Y.; Li, J.; Yu, X.; Li, S.; Zhang X.; Mo Z.; Hu Y. Apc gene hypermethylation and prostate cancer: A systematic review and meta-analysis. Eur. J. Hum. Genet. 2013, 21, 929–935.
138. Pan J.; Chen J.; Zhang B.; Chen X.; Huang B.; Zhuang J.; Mo C.; Qiu S. Association between rassf1a promoter methylation and prostate cancer: A systematic review and meta-analysis. PloS One2013, 8, e75283.
139. Yin, A.A.; Zhang L.H.; Cheng, J.X.; Dong, Y.; Liu, B.L.; Han, N.; Zhang X. The predictive but not prognostic value of mgmt promoter methylation status in elderly glioblastoma patients: A meta-analysis. PloS One2014, 9, e85102.
140. Zhang K.; Wang, X.Q.; Zhou, B.; Zhang L. The prognostic value of mgmt promoter methylation in glioblastoma multiforme: A meta-analysis. Fam. cancer2013, 12, 449–458.
141. Preusser, M.; Berghoff, A.S.; Manzl, C.; Filipits, M.; Weinhausel, A.; Pulverer, W.; Dieckmann, K.; Widhalm, G.; Wohrer, A.; Knosp E.; et al.Clinical neuropathology practice news 1–2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of mgmt promoter methylation status in glioblastoma. Clin. Neuropathol. 2014, 33, 6–14.
142. Quillien, V.; Lavenu, A.; Sanson, M.; Legrain, M.; Dubus, P.; Karayan-Tapon, L.; Mosser, J.; Ichimura, K.; Figarella-Branger, D. Outcome-based determination of optimal pyrosequencing assay for mgmt methylation detection in glioblastoma patients. J. Neurooncol. 2014, 116, 487–496.
143. Dunn, J.; Baborie, A.; Alam, F.; Joyce, K.; Moxham, M.; Sibson, R.; Crooks, D.; Husband, D.; Shenoy, A.; Brodbelt A.; et al.Extent of mgmt promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br. J. Cancer2009, 101, 124–131.
144. Reifenberger, G.; Hentschel, B.; Felsberg, J.; Schackert, G.; Simon, M.; Schnell, O.; Westphal, M.; Wick, W.; Pietsch T.; Loeffler M.; et al.Predictive impact of mgmt promoter methylation in glioblastoma of the elderly. Int. J. Cancer. 2012, 131, 1342–1350.
145. Oberstadt, M.C.; Bien-Moller, S.; Weitmann, K.; Herzog, S.; Hentschel, K.; Rimmbach, C.; Vogelgesang, S.; Balz, E.; Fink, M.; Michael H.; et al.Epigenetic modulation of the drug resistance genes mgmt, abcb1 and abcg2 in glioblastoma multiforme. BMC Cancer2013, 13, 617.
146. Everhard, S.; Tost, J.; el Abdalaoui, H.; Criniere, E.; Busato F.; Marie, Y.; Gut, I.G.; Sanson, M.; Mokhtari, K.; Laigle-Donadey F.; et al.Identification of regions correlating mgmt promoter methylation and gene expression in glioblastomas. Neuro-oncology2009, 11, 348–356.
147. Heyn, H.; Esteller M. DNA methylation profiling in the clinic: Applications and challenges. Nat. Rev. Genet. 2012, 13, 679–692.
148. Delpu, Y.; Cordelier, P.; Cho, W.C.; Torrisani, J. DNA methylation and cancer diagnosis. Int. J. Mol. Sci. 2013, 14, 15029–15058.
149. Heichman, K.A.; Warren, J.D. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin. Chem. Lab. Med. 2012, 50, 1707–1721.
150. Bardhan, K.; Liu, K. Epigenetics and colorectal cancer pathogenesis. Cancers2013, 5, 676–713.
151. Colussi, D.; Brandi, G.; Bazzoli, F.; Ricciardiello, L. Molecular pathways involved in colorectal cancer: Implications for disease behavior and prevention. Int. J. Mol. Sci. 2013, 14, 16365–16385.
152. Gyparaki, M.T.; Basdra, E.K.; Papavassiliou, A.G. DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer. J. Mol. Med. (Berlin, Germany)2013, 91, 1249–1256.
153. Balgkouranidou, I.; Liloglou, T.; Lianidou, E.S. Lung cancer epigenetics: Emerging biomarkers. Biomark. Med. 2013, 7, 49–58.
154. Jones, A.; Lechner, M.; Fourkala, E.O.; Kristeleit, R.; Widschwendter, M. Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women’s cancers. Epigenomics2010, 2, 9–38.
155. Day, T.K.; Bianco-Miotto, T. Common gene pathways and families altered by DNA methylation in breast and prostate cancers. Endocr. Relat. Cancer2013, 20, R215–R232.
156. Kandimalla, R.; van Tilborg, A.A.; Zwarthoff, E.C. DNA methylation-based biomarkers in bladder cancer. Nat. Rev. Urol. 2013, 10, 327–335.
157. Fukushige, S.; Horii, A. Road to early detection of pancreatic cancer: Attempts to utilize epigenetic biomarkers. Cancer Lett. 2014, 342, 231–237.
158. Greenberg, E.S.; Chong, K.K.; Huynh, K.T.; Tanaka, R.; Hoon D.S. Epigenetic biomarkers in skin cancer. Cancer Lett. 2014, 342, 170–177.
159. Zoratto, F.; Rossi, L.; Verrico, M.; Papa, A.; Basso, E.; Zullo, A.; Tomao L.; Romiti, A.; Lo Russo, G.; Tomao S. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: Implications for molecular diagnosis. Tumour Biol. 2014, 35, 6195–6206.
160. McDevitt, M.A. Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies. Semin. Oncol. 2012, 39, 109–122.
161. Rodriguez-Vicente, A.E.; Diaz, M.G.; Hernandez-Rivas, J.M. Chronic lymphocytic leukemia: A clinical and molecular heterogenous disease. Cancer Genet. 2013, 206, 49–62.
162. Li, Y.S.; Xie, Q.; Yang, D.Y.; Zheng, Y. Role of rassf1a promoter methylation in the pathogenesis of hepatocellular carcinoma: A meta-analysis of 21 cohort studies. Mol. Biol. Rep. 2014, 41, 3925–3933.
163. Chen W.D.; Han, Z.J.; Skoletsky, J.; Olson, J.; Sah, J.; Myeroff, L.; Platzer, P.; Lu, S.; Dawson, D.; Willis J.; et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl. Cancer Inst. 2005, 97, 1124–1132.
164. deVos, T.; Tetzner, R.; Model, F.; Weiss, G.; Schuster, M.; Distler, J.; Steiger, K.V.; Grutzmann, R.; Pilarsky, C.; Habermann J.K.; et al. Circulating methylated sept9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem. 2009, 55, 1337–1346.
165. Oh, T.; Kim, N.; Moon, Y.; Kim, M.S.; Hoehn, B.D.; Park, C.H.; Kim, T.S.; Kim, N.K.; Chung, H.C.; An, S. Genome-wide identification and validation of a novel methylation biomarker, sdc2, for blood-based detection of colorectal cancer. J. Mol. Diagn. 2013, 15, 498–507.
166. Mitchell, S.M.; Ross, J.P.; Drew, H.R.; Ho, T.; Brown, G.S.; Saunders, N.F.; Duesing, K.R.; Buckley, M.J.; Dunne, R.; Beetson I.; et al.A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer2014, 14, 54.
167. Goessl, C.; Krause, H.; Muller, M.; Heicappell, R.; Schrader, M.; Sachsinger, J.; Miller, K. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 2000, 60, 5941–5945.
168. Goessl, C.; Muller, M.; Heicappell, R.; Krause, H.; Straub, B.; Schrader, M.; Miller, K. DNA-based detection of prostate cancer in urine after prostatic massage. Urology2001, 58, 335–338.
169. Merlo, A.; Herman, J.G.; Mao, L.; Lee, D.J.; Gabrielson, E.; Burger, P.C.; Baylin, S.B.; Sidransky, D. 5’ cpg island methylation is associated with transcriptional silencing of the tumour suppressor p16/cdkn2/mts1 in human cancers. Nat. Med. 1995, 1, 686–692.
170. Sterlacci, W.; Tzankov, A.; Veits, L.; Zelger, B.; Bihl, M.P.; Foerster, A.; Augustin, F.; Fiegl, M.; Savic, S. A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas. J. Thorac. Oncol. 2011, 6, 1649–1657.
171. Nimmrich, I.; Sieuwerts, A.M.; Meijer-van Gelder, M.E.; Schwope, I.; Bolt-de Vries, J.; Harbeck, N.; Koenig, T.; Hartmann, O.; Kluth, A.; Dietrich D.; et al.DNA hypermethylation of pitx2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res. Treat.2008, 111, 429–437.
172. Harbeck, N.; Nimmrich, I.; Hartmann, A.; Ross, J.S.; Cufer, T.; Grutzmann, R.; Kristiansen, G.; Paradiso, A.; Hartmann, O.; Margossian A.; et al.Multicenter study using paraffin-embedded tumor tissue testing pitx2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J. Clin. Oncol. 2008, 26, 5036–5042.
173. Maier, S.; Nimmrich, I.; Koenig, T.; Eppenberger-Castori, S.; Bohlmann, I.; Paradiso, A.; Spyratos, F.; Thomssen, C.; Mueller, V.; Nahrig J.; et al.DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients—Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur. J. Cancer2007, 43, 1679–1686.
174. Hartmann, O.; Spyratos, F.; Harbeck, N.; Dietrich D.; Fassbender, A.; Schmitt, M.; Eppenberger-Castori, S.; Vuaroqueaux, V.; Lerebours, F.; Welzel K.; et al.DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin. Cancer Res. 2009, 15, 315–323.
175. Banez, L.L.; Sun, L.; van Leenders, G.J.; Wheeler, T.M.; Bangma, C.H.; Freedland S.J.; Ittmann, M.M.; Lark, A.L.; Madden, J.F.; Hartman A.; et al.Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J. Urol. 2010, 184, 149–156.
176. Dietrich D.; Hasinger, O.; Banez, L.L.; Sun, L.; van Leenders, G.J.; Wheeler, T.M.; Bangma, C.H.; Wernert, N.; Perner, S.; Freedland S.J.; et al. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J. Mol. Diagn. 2013, 15, 270–279.
177. Weiss, G.; Cottrell, S.; Distler, J.; Schatz, P.; Kristiansen, G.; Ittmann, M.; Haefliger, C.; Lesche, R.; Hartmann, A.; Corman J.; et al.DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J. Urol. 2009, 181, 1678–1685.
178. Kaina, B.; Christmann, M.; Naumann, S.; Roos, W.P. MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair2007, 6, 1079–1099.
179. Sharma, S.; Salehi, F.; Scheithauer, B.W.; Rotondo, F.; Syro, L.V.; Kovacs, K. Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res. 2009, 29, 3759–3768.
180. Esteller M.; Gaidano, G.; Goodman, S.N.; Zagonel, V.; Capello, D.; Botto, B.; Rossi, D.; Gloghini, A.; Vitolo, U.; Carbone A.; et al.Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 2002, 94, 26–32.
181. Van den Bent, M.J.; Dubbink, H.J.; Sanson, M.; van der Lee-Haarloo, C.R.; Hegi M.; Jeuken J.W.; Ibdaih A.; Brandes A.A.; Taphoorn M.J.; Frenay M.; et al.MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC Brain Tumor Group Study 26951. J. Clin. Oncol. 2009, 27, 5881–5886.
182. Wick, W.; Hartmann, C.; Engel, C.; Stoffels, M.; Felsberg, J.; Stockhammer, F.; Sabel, M.C.; Koeppen, S.; Ketter, R.; Meyermann R.; et al.NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 2009, 27, 5874–5880.
183. Skaar, D.A.; Li, Y.; Bernal, A.J.; Hoyo, C.; Murphy, S.K.; Jirtle, R.L. The human imprintome: Regulatory mechanisms, methods of ascertainment, and roles in disease susceptibility. ILAR J. 2012, 53, 341–358.
184. Peters J. The role of genomic imprinting in biology and disease: An expanding view. Nat. Rev. Genet. 2014, 15, 517–530.
185. Butler M.G. Genomic imprinting disorders in humans: A mini-review. J. Assist. Reprod. Genet. 2009,26, 477–486.
186. Ramsden, S.C.; Clayton-Smith J.; Birch, R.; Buiting, K. Practice guidelines for the molecular analysis of Prader-Willi and Angelman syndromes. BMC Med. Genet. 2010, 11, 70.
187. Boyle, J.; Hawkins, M.; Barton, D.E.; Meaney, K.; Guitart, M.; O’Grady, A.; Tobi, S.; Ramsden, S.C.; Elles, R.; Gray E.; et al.Establishment of the first WHO international genetic reference panel for Prader Willi and Angelman syndromes. Eur. J. Hum. Genet. 2011, 19, 857–864.
188. Kubota, T.; Das, S.; Christian, S.L.; Baylin, S.B.; Herman, J.G.; Ledbetter, D.H. Methylation-specific PCR simplifies imprinting analysis. Nat. Genet. 1997, 16, 16–17.
189. Zeschnigk, M.; Lich, C.; Buiting, K.; Doerfler, W.; Horsthemke, B. A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus. Eur. J. Hum. Genet. 1997, 5, 94–98.
190. Henkhaus, R.S.; Kim, S.J.; Kimonis, V.E.; Gold, J.A.; Dykens, E.M.; Driscoll, D.J.; Butler M.G. Methylation-specific multiplex ligation-dependent probe amplification and identification of deletion genetic subtypes in Prader-Willi syndrome. Genet. Test. Mol. Biomark. 2012, 16, 178–186.
191. Bourque, D.K.; Penaherrera, M.S.; Yuen, R.K.; van Allen, M.I.; McFadden, D.E.; Robinson, W.P. The utility of quantitative methylation assays at imprinted genes for the diagnosis of fetal and placental disorders. Clin. Genet. 2011, 79, 169–175.
192. Eggermann, T.; Begemann, M.; Binder, G.; Spengler, S. Silver-Russell syndrome: Genetic basis and molecular genetic testing. Orphanet J. Rare Dis. 2010, 5, 19.
193. Weksberg R.; Shuman C.; Beckwith J.B. Beckwith-Wiedemann syndrome. Eur. J. Hum. Genet. 2010,18, 8–14.
194. Smilinich, N.J.; Day, C.D.; Fitzpatrick, G.V.; Caldwell, G.M.; Lossie, A.C.; Cooper, P.R.; Smallwood, A.C.; Joyce, J.A.; Schofield, P.N.; Reik W.; et al.A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome. Proc. Natl. Acad. Sci. USA1999, 96, 8064–8069.
195. Horike, S.; Ferreira, J.C.; Meguro-Horike, M.; Choufani, S.; Smith A.C.; Shuman C.; Meschino, W.; Chitayat, D.; Zackai, E.; Scherer S.W.; et al.Screening of DNA methylation at the H19 promoter or the distal region of its ICR1 ensures efficient detection of chromosome 11p15 epimutations in Russell-Silver syndrome. Am. J. Med. Genet. A2009, 149A, 2415–2423.
196. Lukova, M.; Todorova, A.; Todorov, T.; Mitev, V. Different methylation patterns in BWS/SRS cases clarified by MS-MLPA. Mol. Biol. Rep. 2013, 40, 263–268.
197. Priolo, M.; Sparago, A.; Mammi, C.; Cerrato, F.; Lagana, C.; Riccio, A. MS-MLPA is a specific and sensitive technique for detecting all chromosome 11p15.5 imprinting defects of BWS and SRS in a single-tube experiment. Eur. J. Hum. Genet. 2008, 16, 565–571.
198. Scott, R.H.; Douglas, J.; Baskcomb, L.; Nygren, A.O.; Birch, J.M.; Cole, T.R.; Cormier-Daire, V.; Eastwood, D.M.; Garcia-Minaur, S.; Lupunzina P.; et al. Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) robustly detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation. J. Med. Genet.2008, 45, 106–113.
199. Calvello, M.; Tabano, S.; Colapietro, P.; Maitz, S.; Pansa, A.; Augello, C.; Lalatta, F.; Gentilin, B.; Spreafico, F.; Calzari L.; et al.Quantitative DNA methylation analysis improves epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. Epigenetics2013, 8, 1053–1060.
200. White, H.E.; Durston, V.J.; Harvey, J.F.; Cross, N.C. Quantitative analysis of SNRPN(correction of SRNPN) gene methylation by pyrosequencing as a diagnostic test for Prader-Willi syndrome and Angelman syndrome. Clin. Chem. 2006, 52, 1005–1013.
201. Feil, R.; Fraga, M.F. Epigenetics and the environment: Emerging patterns and implications. Nat. Rev. Genet. 2011, 13, 97–109.
202. Mazzio, E.A.; Soliman, K.F. Basic concepts of epigenetics: Impact of environmental signals on gene expression. Epigenetics2012, 7, 119–130.
203. Cortessis, V.K.; Thomas, D.C.; Levine, A.J.; Breton, C.V.; Mack, T.M.; Siegmund, K.D.; Haile, R.W.; Laird, P.W. Environmental epigenetics: Prospects for studying epigenetic mediation of exposure-response relationships. Hum. Genet. 2012, 131, 1565–1589.
204. Hogg, K.; Price, E.M.; Hanna, C.W.; Robinson, W.P. Prenatal and perinatal environmental influences on the human fetal and placental epigenome. Clin. Pharmacol. Ther. 2012, 92, 716–726.
205. Mirbahai L.; Chipman J.K. Epigenetic memory of environmental organisms: A reflection of lifetime stressor exposures. Mutat. Res. Genet. Toxicol. Environ. Mutagen.2014, 764–765, 10–17.
206. Bibikova, M.; Barnes, B.; Tsan, C.; Ho, V.; Klotzle, B.; Le, J.M.; Delano, D.; Zhang L.; Schroth, G.P.; Gunderson K.L.; et al.High density DNA methylation array with single CpG site resolution. Genomics2011, 98, 288–295.
207. Dogan, M.V.; Shields, B.; Cutrona, C.; Gao L.; Gibbons, F.X.; Simons, R.; Monick, M.; Brody, G.H.; Tan, K.; Beach S.R.; et al.The effect of smoking on DNA methylation of peripheral blood mononuclear cells from African American women. BMC Genomics2014, 15, 151.
208. Elliott, H.R.; Tillin, T.; McArdle, W.L.; Ho, K.; Duggirala, A.; Frayling, T.M.; Davey Smith G.; Hughes, A.D.; Chaturvedi, N.; Relton, C.L. Differences in smoking associated DNA methylation patterns in South Asians and Europeans. Clin. Epigenetics2014, 6, 4.
209. Joubert, B.R.; Haberg, S.E.; Nilsen, R.M.; Wang, X.; Vollset S.E.; Murphy, S.K.; Huang Z.; Hoyo, C.; Midttun O.; Cupul-Uicab, L.A.; et al.450K epigenome-wide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy. Environ. Health Perspect.2012, 120, 1425–1431.
210. Philibert, R.A.; Beach S.R.; Lei, M.K.; Brody, G.H. Changes in DNA methylation at the aryl hydrocarbon receptor repressor may be a new biomarker for smoking. Clin. Epigenetics2013, 5, 19.
211. Shenker, N.S.; Polidoro, S.; van Veldhoven, K.; Sacerdote, C.; Ricceri, F.; Birrell, M.A.; Belvisi, M.G.; Brown, R.; Vineis, P.; Flanagan, J.M. Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum. Mol. Genet. 2013, 22, 843–851.
212. Zeilinger, S.; Kuhnel, B.; Klopp, N.; Baurecht, H.; Kleinschmidt, A.; Gieger, C.; Weidinger, S.; Lattka, E.; Adamski, J.; Peters A.; et al.Tobacco smoking leads to extensive genome-wide changes in DNA methylation. PLoS One2013, 8, e63812.
213. Monick, M.M.; Beach S.R.; Plume, J.; Sears, R.; Gerrard, M.; Brody, G.H.; Philibert, R.A. Coordinated changes in AHRR methylation in lymphoblasts and pulmonary macrophages from smokers. Am.J. Med. Genet. B Neuropsychiatr. Genet. 2012, 159B, 141–151.
214. Besingi, W.; Johansson, A. Smoke-related DNA methylation changes in the etiology of human disease. Hum. Mol. Genet. 2014, 23, 2290–2297.
215. Markunas, C.A.; Xu, Z.; Harlid, S.; Wade, P.A.; Lie, R.T.; Taylor, J.A.; Wilcox, A.J. Identification of DNA Methylation Changes in Newborns Related to Maternal Smoking during Pregnancy. Environ. Health Perspect. 2014, doi:10.1289/ehp.1307892.
216. Harlid, S.; Xu, Z.; Panduri, V.; Sandler, D.P.; Taylor, J.A. CpG Sites Associated with Cigarette Smoking: Analysis of Epigenome-Wide Data from the Sister Study. Environ. Health Perspect. 2014, 122, 673–678.
217. Novakovic, B.; Ryan, J.; Pereira, N.; Boughton, B.; Craig J.M.; Saffery R. Postnatal stability, tissue, and time specific effects of AHRR methylation change in response to maternal smoking in pregnancy. Epigenetics2014, 9, 377–386.
218. Joubert, B.R.; Haberg, S.E.; Bell D.A.; Nilsen, R.M.; Vollset S.E.; Midttun O.; Ueland P.M.; Wu, M.C.; Nystad W.; Peddada, S.D.; et al. Maternal Smoking and DNA Methylation in Newborns: In Utero Effect or Epigenetic Inheritance? Cancer Epidemiol. Biomark. Prev. 2014, doi:10.1158/1055-9965.EPI-13-1256.
219. Brokken, L.J.; Lundberg-Giwercman, Y.; Meyts, E.R.; Eberhard, J.; Stahl, O.; Cohn-Cedermark, G.; Daugaard, G.; Arver, S.; Giwercman, A. Association between polymorphisms in the aryl hydrocarbon receptor repressor gene and disseminated testicular germ cell cancer. Front. Endocrinol. 2013, 4, 4.
220. Cauchi, S.; Stucker, I.; Cenee, S.; Kremers, P.; Beaune, P.; Massaad-Massade, L. Structure and polymorphisms of human aryl hydrocarbon receptor repressor (AhRR) gene in a French population: Relationship with CYP1A1 inducibility and lung cancer. Pharmacogenetics2003, 13, 339–347.
221. Liang, Y.; Li, W.W.; Yang, B.W.; Tao, Z.H.; Sun, H.C.; Wang, L.; Xia, J.L.; Qin, L.X.; Tang, Z.Y.; Fan J.; et al.Aryl hydrocarbon receptor nuclear translocator is associated with tumor growth and progression of hepatocellular carcinoma. Int.J. Cancer2012, 130, 1745–1754.
222. Tsuchiya, M.; Katoh, T.; Motoyama, H.; Sasaki, H.; Tsugane, S.; Ikenoue T. Analysis of the AhR, ARNT, and AhRR gene polymorphisms: Genetic contribution to endometriosis susceptibility and severity. Fertil. Steril. 2005, 84, 454–458.
223. Lupien, S.J.; McEwen, B.S.; Gunnar, M.R.; Heim, C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat. Rev. Neurosci. 2009, 10, 434–445.
224. Meaney, M.J.; Szyf, M. Environmental programming of stress responses through DNA methylation: Life at the interface between a dynamic environment and a fixed genome. Dialogues Clin. Neurosci. 2005, 7, 103–123.
225. Weaver, I.C.; Cervoni, N.; Champagne, F.A.; D’Alessio, A.C.; Sharma, S.; Seckl, J.R.; Dymov, S.; Szyf, M.; Meaney, M.J. Epigenetic programming by maternal behavior. Nat. Neurosci. 2004, 7, 847–854.
226. Oberlander, T.F.; Weinberg, J.; Papsdorf, M.; Grunau, R.; Misri, S.; Devlin, A.M. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics2008, 3, 97–106.
227. Hompes, T.; Izzi, B.; Gellens, E.; Morreels, M.; Fieuws, S.; Pexsters, A.; Schops, G.; Dom, M.; van Bree, R.; Freson K.; et al. Investigating the influence of maternal cortisol and emotional state during pregnancy on the DNA methylation status of the glucocorticoid receptor gene (NR3C1) promoter region in cord blood. J. Psychiatr. Res. 2013, 47, 880–891.
228. Conradt, E.; Lester, B.M.; Appleton, A.A.; Armstrong, D.A.; Marsit, C.J. The roles of DNA methylation of NR3C1 and 11beta-HSD2 and exposure to maternal mood disorder in utero on newborn neurobehavior. Epigenetics2013, 8, 1321–1329.
229. Radtke, K.M.; Ruf, M.; Gunter, H.M.; Dohrmann, K.; Schauer, M.; Meyer, A.; Elbert, T. Transgenerational impact of intimate partner violence on methylation in the promoter of the glucocorticoid receptor. Transl. Psychiatry2011, 1, e21.
230. Mulligan, C.J.; D’Errico, N.C.; Stees, J.; Hughes, D.A. Methylation changes at NR3C1 in newborns associate with maternal prenatal stress exposure and newborn birth weight. Epigenetics2012, 7, 853–857.
231. Yehuda, R.; Daskalakis, N.P.; Lehrner, A.; Desarnaud, F.; Bader, H.N.; Makotkine, I.; Flory, J.D.; Bierer, L.M.; Meaney, M.J. Influences of Maternal and Paternal PTSD on Epigenetic Regulation of the Glucocorticoid Receptor Gene in Holocaust Survivor Offspring. Am. J. Psychiatry2014, 171, 872–880.
232. McGowan, P.O.; Sasaki, A.; D’Alessio, A.C.; Dymov, S.; Labonte, B.; Szyf, M.; Turecki, G.; Meaney, M.J. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat. Neurosci. 2009, 12, 342–348.
233. Perroud, N.; Paoloni-Giacobino, A.; Prada, P.; Olie, E.; Salzmann, A.; Nicastro, R.; Guillaume, S.; Mouthon, D.; Stouder, C.; Dieben K.; et al. Increased methylation of glucocorticoid receptor gene (NR3C1) in adults with a history of childhood maltreatment: A link with the severity and type of trauma. Transl. Psychiatry2011, 1, e59.
234. Labonte, B.; Yerko, V.; Gross, J.; Mechawar, N.; Meaney, M.J.; Szyf, M.; Turecki, G. Differential glucocorticoid receptor exon 1(B), 1(C), and 1(H) expression and methylation in suicide completers with a history of childhood abuse. Biol. Psychiatry2012, 72, 41–48.
235. Tyrka, A.R.; Price, L.H.; Marsit, C.; Walters, O.C.; Carpenter, L.L. Childhood adversity and epigenetic modulation of the leukocyte glucocorticoid receptor: Preliminary findings in healthy adults. PLoS One2012, 7, e30148.
236. Melas, P.A.; Wei, Y.; Wong, C.C.; Sjoholm, L.K.; Aberg, E.; Mill, J.; Schalling, M.; Forsell, Y.; Lavebratt, C. Genetic and epigenetic associations of MAOA and NR3C1 with depression and childhood adversities. Int. J. Neuropsychopharmacol. 2013, 16, 1513–1528.
237. Yehuda, R.; Flory, J.D.; Bierer, L.M.; Henn-Haase, C.; Lehrner, A.; Desarnaud, F.; Makotkine, I.; Daskalakis, N.P.; Marmar, C.R.; Meaney, M.J. Lower Methylation of Glucocorticoid Receptor Gene Promoter 1 in Peripheral Blood of Veterans with Posttraumatic Stress Disorder. Biol. Psychiatry2014, doi:10.1016/j.biopsych.2014.02.006.
238. Labonte, B.; Azoulay, N.; Yerko, V.; Turecki, G.; Brunet, A. Epigenetic modulation of glucocorticoid receptors in posttraumatic stress disorder. Transl. Psychiatry2014, 4, e368.
239. Bromer, C.; Marsit, C.J.; Armstrong, D.A.; Padbury, J.F.; Lester, B. Genetic and epigenetic variation of the glucocorticoid receptor (NR3C1) in placenta and infant neurobehavior. Dev. Psychobiol. 2013, 55, 673–683.
240. Yehuda, R.; Daskalakis, N.P.; Desarnaud, F.; Makotkine, I.; Lehrner, A.L.; Koch, E.; Flory, J.D.; Buxbaum, J.D.; Meaney, M.J.; Bierer, L.M. Epigenetic Biomarkers as Predictors and Correlates of Symptom Improvement Following Psychotherapy in Combat Veterans with PTSD. Front. Psychiatry2013, 4, 118.
241. Edelman, S.; Shalev, I.; Uzefovsky, F.; Israel, S.; Knafo, A.; Kremer, I.; Mankuta, D.; Kaitz, M.; Ebstein, R.P. Epigenetic and genetic factors predict women’s salivary cortisol following a threat to the social self. PLoS One2012, 7, e48597.
242. Weaver, I.C.; Champagne, F.A.; Brown, S.E.; Dymov, S.; Sharma, S.; Meaney, M.J.; Szyf, M. Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: Altering epigenetic marking later in life. J. Neurosci.2005, 25, 11045–11054.
243. Weaver, I.C.; Meaney, M.J.; Szyf, M. Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. Proc. Natl. Acad. Sci. USA2006, 103, 3480–3485.
244. Essex, M.J.; Thomas Boyce, W.; Hertzman, C.; Lam, L.L.; Armstrong, J.M.; Neumann, S.M.; Kobor, M.S. Epigenetic Vestiges of Early Developmental Adversity: Childhood Stress Exposure and DNA Methylation in Adolescence. Child Dev. 2011, doi:10.1111/j.1467-8624.2011.01641.x.
245. Uddin, M.; Aiello, A.E.; Wildman, D.E.; Koenen, K.C.; Pawelec, G.; de Los Santos, R.; Goldmann, E.; Galea, S. Epigenetic and immune function profiles associated with posttraumatic stress disorder. Proc. Natl. Acad. Sci. USA2010, 107, 9470–9475.
246. Borghol, N.; Suderman, M.; McArdle, W.; Racine, A.; Hallett, M.; Pembrey, M.; Hertzman, C.; Power, C.; Szyf, M. Associations with early-life socio-economic position in adult DNA methylation. Int. J. Epidemiol. 2012, 41, 62–74.
247. Mehta, D.; Klengel, T.; Conneely, K.N.; Smith A.K.; Altmann, A.; Pace, T.W.; Rex-Haffner, M.; Loeschner, A.; Gonik, M.; Mercer K.B.; et al. Childhood maltreatment is associated with distinct genomic and epigenetic profiles in posttraumatic stress disorder. Proc. Natl. Acad. Sci. USA2013, 110, 8302–8307.
248. Naumova, O.Y.; Lee, M.; Koposov, R.; Szyf, M.; Dozier, M.; Grigorenko, E.L. Differential patterns of whole-genome DNA methylation in institutionalized children and children raised by their biological parents. Dev. Psychopathol. 2012, 24, 143–155.
249. Harvey, N.C.; Sheppard, A.; Godfrey, K.M.; McLean, C.; Garratt, E.; Ntani, G.; Davies, L.; Murray, R.; Inskip, H.M.; Gluckman P.D.; et al.Childhood Bone Mineral Content Is Associated With Methylation Status of the RXRA Promoter at Birth. J. Bone Miner. Res. 2014, 29, 600–607.
250. Relton, C.L.; Groom, A.; St Pourcain, B.; Sayers, A.E.; Swan, D.C.; Embleton, N.D.; Pearce, M.S.; Ring, S.M.; Northstone, K.; Tobias J.H.; et al.DNA methylation patterns in cord blood DNA and body size in childhood. PLoS One2012, 7, e31821.
251. Rakyan V.K.; Beyan H.; Down T.A.; Hawa M.I.; Maslau S.; Aden D.; Daunay A.; Busato F.; Mein C.A.; Manfras B.; et al. Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet. 2011, 7, e1002300.
252. Clarke-Harris, R.; Wilkin, T.J.; Hosking, J.; Pinkney, J.; Jeffery, A.N.; Metcalf, B.S.; Godfrey, K.M.; Voss, L.D.; Lillycrop, K.A.; Burdge, G.C. Peroxisomal proliferator activated receptor-gamma-co-activator-1alpha promoter methylation in blood at 5–7 years predicts adiposity from 9 to 14 years (earlybird 50). Diabetes2014, 63, 2528–2537.
253. Nguyen, A.; Rauch, T.A.; Pfeifer, G.P.; Hu V.W. Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain. FASEB J. 2010, 24, 3036–3051.
254. Wong, C.C.; Meaburn, E.L.; Ronald, A.; Price, T.S.; Jeffries, A.R.; Schalkwyk, L.C.; Plomin, R.; Mill, J. Methylomic analysis of monozygotic twins discordant for autism spectrum disorder and related behavioural traits. Mol. Psychiatry2014, 19, 495–503.
255. Wang, Y.; Fang, Y.; Zhang F.; Xu, M.; Zhang J.; Yan, J.; Ju, W.; Brown, W.T.; Zhong, N. Hypermethylation of the enolase gene (ENO2) in autism. Eur. J. Pediatr. 2014, 173, 1233–1244.
256. Berko E.R.; Suzuki M.; Beren F.; Lemetre C.; Alaimo C.M.; Calder R.B.; Ballaban-Gil K.; Gounder B.; Kampf K.; Kirschen J.; et al.Mosaic epigenetic dysregulation of ectodermal cells in autism spectrum disorder. PLoS Genet. 2014, 10, e1004402.
257. Ginsberg, M.R.; Rubin, R.A.; Falcone, T.; Ting, A.H.; Natowicz, M.R. Brain transcriptional and epigenetic associations with autism. PLoS One2012, 7, e44736.
258. Ladd-Acosta, C.; Hansen, K.D.; Briem, E.; Fallin, M.D.; Kaufmann, W.E.; Feinberg, A.P. Common DNA methylation alterations in multiple brain regions in autism. Mol. Psychiatry2013, doi:10.1038/mp.2013.114.
259. Sun, C.; Burgner, D.P.; Ponsonby, A.L.; Saffery R.; Huang R.C.; Vuillermin, P.J.; Cheung, M.; Craig J.M. Effects of early-life environment and epigenetics on cardiovascular disease risk in children: Highlighting the role of twin studies. Pediatr. Res. 2013, 73, 523–530.
260. Chang, C.P.; Bruneau, B.G. Epigenetics and cardiovascular development. Annu. Rev. Physiol. 2012, 74, 41–68.
261. Shirodkar, A.V.; Marsden, P.A. Epigenetics in cardiovascular disease. Curr. Opin. Cardiol. 2011, 26, 209–215.
262. Hidalgo, B.; Irvin, M.R.; Sha, J.; Zhi, D.; Aslibekyan, S.; Absher, D.; Tiwari, H.K.; Kabagambe, E.K.; Ordovas, J.M.; Arnett, D.K. Epigenome-wide association study of fasting measures of glucose, insulin, and HOMA-IR in the Genetics of Lipid Lowering Drugs and Diet Network study. Diabetes2014, 63, 801–807.
263. Irvin, M.R.; Zhi, D.; Joehanes, R.; Mendelson, M.; Aslibekyan, S.; Claas, S.A.; Thibeault, K.S.; Patel, N.; Day, K.; Waite Jones L.; et al.Epigenome-Wide Association Study of Fasting Blood Lipids in the Genetics of Lipid Lowering Drugs and Diet Network Study. Circulation2014, 130, 565–572.
264. Campion J.; Milagro, F.I.; Martinez, J.A. Individuality and epigenetics in obesity. Obes. Rev. 2009, 10, 383–392.
265. Toperoff, G.; Aran, D.; Kark, J.D.; Rosenberg, M.; Dubnikov, T.; Nissan, B.; Wainstein, J.; Friedlander, Y.; Levy-Lahad, E.; Glaser B.; et al.Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood. Hum. Mol. Genet. 2012, 21, 371–383.
266. Cordero, P.; Campion J.; Milagro, F.I.; Goyenechea, E.; Steemburgo, T.; Javierre, B.M.; Martinez, J.A. Leptin and TNF-alpha promoter methylation levels measured by MSP could predict the response to a low-calorie diet. J.Physiol. Biochem. 2011, 67, 463–470.
267. Guintivano, J.; Arad, M.; Gould, T.D.; Payne J.L.; Kaminsky, Z.A. Antenatal prediction of postpartum depression with blood DNA methylation biomarkers. Mol. Psychiatry2014, 19, 633.
268. Wockner, L.F.; Noble, E.P.; Lawford, B.R.; Young, R.M.; Morris, C.P.; Whitehall, V.L.; Voisey, J. Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. Transl. Psychiatry2014, 4, e339.
269. Nishioka, M.; Bundo, M.; Koike, S.; Takizawa, R.; Kakiuchi, C.; Araki, T.; Kasai, K.; Iwamoto, K. Comprehensive DNA methylation analysis of peripheral blood cells derived from patients with first-episode schizophrenia. J. Hum. Genet.2013, 58, 91–97.
270. Xiao, Y.; Camarillo, C.; Ping, Y.; Arana, T.B.; Zhao, H.; Thompson, P.M.; Xu, C.; Su, B.B.; Fan H.; Ordonez J.; et al.The DNA methylome and transcriptome of different brain regions in schizophrenia and bipolar disorder. PLoS One2014, 9, e95875.
271. Aberg, K.A.; McClay, J.L.; Nerella, S.; Clark S.; Kumar, G.; Chen W.; Khachane, A.N.; Xie, L.; Hudson, A.; Gao G.; et al. Methylome-wide association study of schizophrenia: Identifying blood biomarker signatures of environmental insults. JAMA Psychiatry2014, 71, 255–264.
272. Abdolmaleky, H.M.; Nohesara, S.; Ghadirivasfi, M.; Lambert, A.W.; Ahmadkhaniha, H.; Ozturk, S.; Wong, C.K.; Shafa, R.; Mostafavi, A.; Thiagalingam, S. DNA hypermethylation of serotonin transporter gene promoter in drug naive patients with schizophrenia. Schizophr. Res. 2014, 152, 373–380.
273. Nishioka, M.; Bundo, M.; Kasai, K.; Iwamoto, K. DNA methylation in schizophrenia: Progress and challenges of epigenetic studies. Genome Med. 2012, 4, 96.
274. Kato, T.; Iwamoto, K. Comprehensive DNA methylation and hydroxymethylation analysis in the human brain and its implication in mental disorders. Neuropharmacology2014, 80, 133–139.
275. Abdolmaleky, H.M.; Smith C.L.; Faraone, S.V.; Shafa, R.; Stone, W.; Glatt, S.J.; Tsuang, M.T. Methylomics in psychiatry: Modulation of gene-environment interactions may be through DNA methylation. Am.J. Med. Genet. B Neuropsychiatr. Genet. 2004, 127B, 51–59.
276. Abdolmaleky, H.M.; Yaqubi, S.; Papageorgis, P.; Lambert, A.W.; Ozturk, S.; Sivaraman, V.; Thiagalingam, S. Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophr. Res. 2011, 129, 183–190.
277. Ghadirivasfi, M.; Nohesara, S.; Ahmadkhaniha, H.R.; Eskandari, M.R.; Mostafavi, S.; Thiagalingam, S.; Abdolmaleky, H.M. Hypomethylation of the serotonin receptor type-2A gene (HTR2A) at T102C polymorphic site in DNA derived from the saliva of patients with schizophrenia and bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011, 156, 536–545.
278. Mill, J.; Tang, T.; Kaminsky, Z.; Khare, T.; Yazdanpanah, S.; Bouchard, L.; Jia, P.; Assadzadeh, A.; Flanagan, J.; Schumacher A.; et al.Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am. J. Hum. Genet. 2008, 82, 696–711.
279. Abdolmaleky, H.M.; Cheng, K.H.; Russo, A.; Smith C.L.; Faraone, S.V.; Wilcox, M.; Shafa, R.; Glatt, S.J.; Nguyen, G.; Ponte J.F.; et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: A preliminary report. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 134B, 60–66.
280. Grayson, D.R.; Jia, X.; Chen Y.; Sharma, R.P.; Mitchell, C.P.; Guidotti, A.; Costa, E. Reelin promoter hypermethylation in schizophrenia. Proc. Natl. Acad. Sci. USA2005, 102, 9341–9346.
281. Kaminsky, Z.; Tochigi, M.; Jia, P.; Pal, M.; Mill, J.; Kwan, A.; Ioshikhes, I.; Vincent, J.B.; Kennedy, J.L.; Strauss J.; et al.A multi-tissue analysis identifies HLA complex group 9 gene methylation differences in bipolar disorder. Mol. Psychiatry2012, 17, 728–740.
282. Sugawara, H.; Iwamoto, K.; Bundo, M.; Ueda, J.; Miyauchi, T.; Komori, A.; Kazuno, A.; Adati, N.; Kusumi, I.; Okazaki Y.; et al.Hypermethylation of serotonin transporter gene in bipolar disorder detected by epigenome analysis of discordant monozygotic twins. Transl. Psychiatry2011, 1, e24.
283. Cruickshank, M.N.; Pitt, J.; Craig J.M. Going back to the future with Guthrie-powered epigenome-wide association studies. Genome Med. 2012, 4, 83.
284. Tsai, P.C.; Spector, T.D.; Bell J.T. Using epigenome-wide association scans of DNA methylation in age-related complex human traits. Epigenomics2012, 4, 511–526.
285. Weidner, C.I.; Lin, Q.; Koch, C.M.; Eisele, L.; Beier, F.; Ziegler, P.; Bauerschlag, D.O.; Jockel, K.H.; Erbel, R.; Muhleisen T.W.; et al. Aging of blood can be tracked by DNA methylation changes at just three CpG sites. Genome Biol. 2014, 15, R24.
286. Horvath, S. DNA methylation age of human tissues and cell types. Genome Biol. 2013, 14, R115.
287. Bibikova, M.; Le, J.; Barnes, B.; Saedinia-Melnyk, S.; Zhou, L.; Shen, R.; Gunderson K.L. Geneom-wide methylation profiling using Infinium assay. Epigenomics2009, 1, 177–200.
288. Hannum, G.; Guinney, J.; Zhao, L.; Zhang L.; Hughes, G.; Sadda, S.; Klotzle, B.; Bibikova, M.; Fan J.B.; Gao Y.; et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol. Cell2013, 49, 359–367.
289. Gibbs, W.W. Biomarkers and ageing: The clock-watcher. Nature2014, 508, 168–170.
290. Ogino, S.; Stampfer, M. Lifestyle factors and microsatellite instability in colorectal cancer: The evolving field of molecular pathological epidemiology. J. Natl. Cancer Inst. 2010, 102, 365–367.
291. Bishehsari, F.; Mahdavinia, M.; Vacca, M.; Malekzadeh, R.; Mariani-Costantini, R. Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention. World J. Gastroenterol. 2014, 20, 6055–6072.
292. Whelan, R.; Watts, R.; Orr, C.A.; Althoff, R.R.; Artiges, E.; Banaschewski, T.; Barker, G.J.; Bokde, A.L.; Buchel, C.; Carvalho F.M.; et al.Neuropsychosocial profiles of current and future adolescent alcohol misusers. Nature2014, 512, 185–189.
293. Kim, D.S.; Lee, J.Y.; Lee, S.M.; Choi, J.E.; Cho, S.; Park, J.Y. Promoter methylation of the RGC32 gene in nonsmall cell lung cancer. Cancer2011, 117, 590–596.